Jointly sponsored by the Division of Pharmaceutics & Pharmaceutical Chemistry
Title: Truncated Androgen Receptor and Intracrine Androgen Synthesis in Resistant Prostate Cancer
Speaker: Allen C. Gao, MD, PhD
Ralph de Vere White Professor and Director of Urologic Research Department of Urology
UC Davis Comprehensive Cancer Center
University of California at Davis
Abstract: Several mechanisms facilitate the progression of hormone-sensitive prostate cancer to castration-resistant prostate cancer (CRPC). At present, the approved therapies for CRPC include systemic drugs (docetaxel and cabazitaxel) and agents that target androgen signaling, including enzalutamide and abiraterone. Over time, however, all patients inevitably develop resistance to treatment and their disease will continue to progress. In this talk, I will present several key mechanisms that give rise to drug resistance including expression of constitutively active variants of the androgen receptor, such as AR-V7; and intracrine androgens and overexpression of androgen synthesis enzymes like AKR1C3. Treatment strategies are being developed to target these pathways and reintroduce drug sensitivity. By better understanding the mechanisms by which drug resistance develops, improved treatment strategies will be made possible.